For the year ending 2025-12-31, TARS has $562,158K in assets. $218,732K in debts.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 183,641 | |||
| Restricted cash | 560 | |||
| Marketable securities | 233,627 | |||
| Accounts receivable, net | 85,057 | |||
| Inventory | 4,372 | |||
| Other receivables | 2,052 | |||
| Prepaid expenses | 13,473 | |||
| Total current assets | 522,782 | |||
| Restricted cash, non-current | 2,002 | |||
| Inventory, non-current | 2,532 | |||
| Property and equipment, net | 11,665 | |||
| Intangible assets, net | 7,366 | |||
| Operating lease right-of-use assets | 10,080 | |||
| Long-term investments | 3,870 | |||
| Other assets | 1,861 | |||
| Total assets | 562,158 | |||
| Accounts payable | 16,387 | |||
| Accrued payroll and benefits | 17,779 | |||
| Other accrued liabilities | 101,529 | |||
| Total current liabilities | 135,695 | |||
| Long-term debt, net | 72,438 | |||
| Other long-term liabilities | 10,599 | |||
| Total liabilities | 218,732 | |||
| Common stock, 0.0001 par value 200,000,000 shares authorized 42,553,931 shares issued and outstanding at december31, 2025 38,349,826 shares issued and outstanding at december31, 2024 | 6 | |||
| Additional paid-in capital | 769,667 | |||
| Accumulated other comprehensive income (loss) | 381 | |||
| Accumulated deficit | -426,628 | |||
| Total stockholders equity | 343,426 | |||
| Total liabilities and stockholders equity | 562,158 | |||
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)